JMP reiterates ViroPharma at market outperform

ViroPharma Inc. was reiterated by JMP Securities analyst Adam Cutler at market outperform as strong end-user demand drove Vanconin sales to $43.8 million for the second quarter, beating both JMP's estimate of $43.1 million and the Street estimate of $42.4 million. Earnings per share for the period met the analyst's estimate and slightly beat consensus of $0.23. Shares of the Exton, Pa.-based pharmaceutical company were up 25 cents, or 2.90%, at $8.87, on volume of 3,302,839 shares versus the three-month running average of 1,987,170 shares. (Nasdaq: VPHM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.